Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Enliven Therapeutics Inc (NASDAQ: ELVN) closed at $17.69 down -1.17% from its previous closing price of $17.9. In other words, the price has decreased by -$1.17 from its previous closing price. On the day, 0.57 million shares were traded. ELVN stock price reached its highest trading level at $18.42 during the session, while it also had its lowest trading level at $17.4275.
Ratios:
For a deeper understanding of Enliven Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.06 and its Current Ratio is at 21.06. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42.
On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 07 ’25 when Patel Anish bought 6,667 shares for $18.84 per share.
Hohl Benjamin sold 3,250 shares of ELVN for $66,504 on Jul 28 ’25. The CHIEF FINANCIAL OFFICER now owns 23,000 shares after completing the transaction at $20.46 per share. On Jul 28 ’25, another insider, Hohl Benjamin, who serves as the Officer of the company, bought 4,250 shares for $21.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 1043536640 and an Enterprise Value of 579147200.
Stock Price History:
The Beta on a monthly basis for ELVN is 0.88, which has changed by -0.17026263 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, ELVN has reached a high of $30.03, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is -14.58%, while the 200-Day Moving Average is calculated to be -18.08%.
Shares Statistics:
For the past three months, ELVN has traded an average of 513.54K shares per day and 393230 over the past ten days. A total of 49.04M shares are outstanding, with a floating share count of 39.28M. Insiders hold about 33.41% of the company’s shares, while institutions hold 62.24% stake in the company. Shares short for ELVN as of 1752537600 were 5543837 with a Short Ratio of 10.80, compared to 1749772800 on 6620560. Therefore, it implies a Short% of Shares Outstanding of 5543837 and a Short% of Float of 13.41.
Earnings Estimates
The market rating of Enliven Therapeutics Inc (ELVN) is currently shaped by the ongoing analysis conducted by 2 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.4 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.59 and -$1.59 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.64, with 1.0 analysts recommending between -$1.64 and -$1.64.
